Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228514 | 0.87 | CA1 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4747234 | 0.87 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28878705 | 0.84 | NOTUM (0.54) | NOTUMCA12CA1CA2CA7 | |
| SCHEMBL2825003 | 0.83 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16956412 | 0.83 | NOTUM (0.53) | NOTUMCA12CA1CA2CA7 | |
| SCHEMBL21248382 | 0.83 | NOTUM (0.53) | NOTUMCA12CA1CA2CA7 | |
| SCHEMBL5102877 | 0.82 | GABRA1 (0.39) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL2225066 | 0.81 | MRGPRX4 (0.45) | CA12CA1CA2CA7CA9 | |
| Methyl 3,5-Dibromobenzoate SCHEMBL2408987 | 0.81 | NOTUM (0.67) | NOTUMCA12CA1CA2CA7 | |
| SCHEMBL184614 | 0.81 | NOTUM (0.67) | NOTUMCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| CN-113939288-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119522227-A | Macrocyclic compounds, pharmaceutical compositions and uses thereof | 贝达药业股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240390350-A1 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2024-11-28 | — | — | US | disclosed |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-12 | — | — | US | disclosed |
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-08-08 | — | — | US | disclosed |
| EP-4402137-A1 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | Vanderbilt University (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118234718-A | Phenyl core compounds as MGLU5 negative allosteric modulators and methods of making and using the same | 范德比尔特大学 | 2024-06-21 | — | — | CN | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| WO-2024017358-A1 | MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 贝达药业股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1679313-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| CN-1649865-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390350-A1 | PHENYL CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | NOTUM 2529/4885CA12 4642/4885CA1 3118/4885 |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | NOTUM 3543/4885CA12 3922/4885CA1 972/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | NOTUM 4535/4885CA12 1748/4885CA1 1377/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | NOTUM 3543/4885CA12 3922/4885CA1 972/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | NOTUM 3543/4885CA12 3922/4885CA1 972/4885 |
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | NOTUM 1802/4885CA12 4547/4885CA1 4318/4885 |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | NOTUM 1902/4885CA12 4458/4885CA1 4348/4885 |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | NOTUM 4318/4885CA12 2960/4885CA1 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.